复宏汉霖：Accelerating global commercialization and innovation-20260324

24 Mar 2026 CMB International Global Markets | Equity Research | Company Update Henlius Biotech (2696 HK) Henlius Biotech (2696 HK) - Accelerating global commercialization and innovation innovation Henlius delivered strong FY25 financial results, driven by robust product sales growth. The Company is expanding its global biosimilar footprint and forging new international partnerships. Henlius is accelerating its evolution into an innovative biologics powerhouse, spearheaded by competitive assets such as HLX4 ...